Back to top
more

Zynerba Pharmaceuticals, Inc. (ZYNE)

(Delayed Data from NSDQ)

$11.45 USD

11.45
2,372,198

+0.35 (3.15%)

Updated May 3, 2019 04:00 PM ET

After-Market: $11.45 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Zynerba (ZYNE) Upgraded to Buy: What Does It Mean for the Stock?

Zynerba (ZYNE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sanghamitra Saha headshot

Rising P/E: An Overlooked Way to Pick 5 Winning Stocks

Want to try a different approach? Tap five stocks with increasing P/E ratios. These include CuriosityStream (CURI), Root (ROOT), LendingClub (LC), Manitex International (MNTX) and Zynerba Pharmaceuticals (ZYNE).

Zynerba (ZYNE) Loses 29.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zynerba (ZYNE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Sweta Killa headshot

Inside the Top-Performing ETFs of Q1

Amplify Seymour Cannabis ETF (CNBS) topped the list of the best-performing ETFs of February with impressive returns of about 60%.

Zynerba Pharmaceuticals (ZYNE) Gains But Lags Market: What You Should Know

Zynerba Pharmaceuticals (ZYNE) closed at $4.15 in the latest trading session, marking a +1.47% move from the prior day.

Zynerba Pharmaceuticals (ZYNE) Gains As Market Dips: What You Should Know

Zynerba Pharmaceuticals (ZYNE) closed at $4.50 in the latest trading session, marking a +0.78% move from the prior day.

Zynerba Pharmaceuticals (ZYNE) Jumps: Stock Rises 7.7%

Zynerba Pharmaceuticals (ZYNE) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Zynerba Pharmaceuticals (ZYNE) Outpaces Stock Market Gains: What You Should Know

Zynerba Pharmaceuticals (ZYNE) closed the most recent trading day at $3.79, moving +1.34% from the previous trading session.

What's in the Cards for Zynerba (ZYNE) This Earnings Season?

Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the second quarter due to clinical studies on its lead pipeline candidate, Zygel.

Zynerba's Zygel Fails in Phase III Fragile X Syndrome Study

Zynerba's (ZYNE) shares plunge 48.5% following the study data readout, which demonstrated failure to achieve statistical significance in primary endpoint.

Implied Volatility Surging For Zynerba Pharmaceuticals (ZYNE) Stock Options

Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.

Zacks Market Edge Highlights: Canopy Growth, Aurora Cannabis, Hexo, GW Pharmaceuticals and Zynerba

Zacks Market Edge Highlights: Canopy Growth, Aurora Cannabis, Hexo, GW Pharmaceuticals and Zynerba

Tracey Ryniec headshot

Is This a Buying Opportunity in the Marijuana Stocks?

The marijuana stocks plunged during the coronavirus sell-off. Should investors be taking a second look?

Implied Volatility Surging for Zynerba Pharmaceuticals (ZYNE) Stock Options

Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.

Is Zynerba Pharmaceuticals (ZYNE) Stock Outpacing Its Medical Peers This Year?

Is (ZYNE) Outperforming Other Medical Stocks This Year?

Zynerba Pharmaceuticals (ZYNE) Gains But Lags Market: What You Should Know

Zynerba Pharmaceuticals (ZYNE) closed the most recent trading day at $3.47, moving +1.76% from the previous trading session.

Zynerba Pharmaceuticals (ZYNE) Gains But Lags Market: What You Should Know

In the latest trading session, Zynerba Pharmaceuticals (ZYNE) closed at $3.83, marking a +0.17% move from the previous day.

Zynerba Pharmaceuticals (ZYNE) Stock Sinks As Market Gains: What You Should Know

Zynerba Pharmaceuticals (ZYNE) closed at $4.18 in the latest trading session, marking a -1.88% move from the prior day.

What's in the Cards for Zynerba (ZYNE) This Earnings Season?

Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the fourth quarter driven by clinical studies on its lead pipeline candidate, Zygel.

Zynerba Pharmaceuticals Enters Oversold Territory

Zynerba Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Zynerba Pharmaceuticals (ZYNE) Stock Sinks As Market Gains: What You Should Know

Zynerba Pharmaceuticals (ZYNE) closed the most recent trading day at $5, moving -0.79% from the previous trading session.

Zynerba Pharmaceuticals (ZYNE) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Zynerba Pharmaceuticals (ZYNE) closed at $5.20, marking a -0.38% move from the previous day.

Zynerba Pharmaceuticals (ZYNE) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Zynerba Pharmaceuticals (ZYNE) closed at $5.70, marking a -0.35% move from the previous day.

Urmimala Biswas headshot

Ride the Cannabis Wave With These 3 Stocks

Here we discuss three best stocks in the emerging cannabis space.

The Zacks Analyst Blog Highlights: Uber, AES, CIRCOR International, Edwards Lifesciences and Zynerba Pharmaceuticals

The Zacks Analyst Blog Highlights: Uber, AES, CIRCOR International, Edwards Lifesciences and Zynerba Pharmaceuticals